Related Experiment Video
Updated: Sep 29, 2025
03:47
Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
Published on: November 1, 2024
288
Changes in halitosis value before and after Helicobacter pylori eradication: A single-institutional prospective study
Yui Kudo1,2, Shin-Ei Kudo1, Hideyuki Miyachi1
1Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.
Journal of Gastroenterology and Hepatology
|March 24, 2022
Summary
Helicobacter pylori eradication therapy significantly improves halitosis, with objective breath measurements showing lasting positive effects. This improvement in bad breath can be sustained for over two years post-treatment.
Area of Science:
- Gastroenterology
- Microbiology
- Otorhinolaryngology
Background:
- Halitosis is often subjectively reported as improved or worsened after Helicobacter pylori eradication.
- Objective data on halitosis changes post-eradication are limited.
Purpose of the Study:
- To objectively investigate changes in halitosis following successful H. pylori eradication.
- To assess the long-term impact of H. pylori eradication on halitosis.
Main Methods:
- Evaluated halitosis using Refres breath (RB) values via a Total Gas Detector™ System.
- Compared RB values before and after successful H. pylori eradication confirmed by urea breath testing.
- Included 91 patients with H. pylori infection undergoing upper gastrointestinal endoscopy.
Main Results:
- Successful H. pylori eradication in 77 patients led to significant RB value improvements (73.5 to 59.4, P=0.038).
- In a subset followed for over 2 years, 8 patients with initial high RB values showed dramatic improvements (77.9 to 30.1, P=0.0016).
Conclusions:
- H. pylori eradication therapy can objectively improve halitosis.
- The positive effects on halitosis are sustainable for at least two years after successful eradication.
Keywords:
Helicobacter infectionsHelicobacter pyloriRefres breath (RB) valueeradication therapyhalitosisurea breath testsMore Related Videos
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
595
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
595
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
219
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
219
01:26Peptic Ulcer Disease IV: Management
153
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
153
01:30Peptic Ulcer Disease I: Introduction
313
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
313
01:23Gastritis III: Clinical Manifestations and Management
548
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
548
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
636
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
636